WO2026047608 - METHODS RELATED TO MULTIPLE MYELOMA AND PRECURSORS THEREOF
National phase entry is expected:
Publication Number
WO/2026/047608
Publication Date
05.03.2026
International Application No.
PCT/IB2025/058719
International Filing Date
29.08.2025
Title **
[English]
METHODS RELATED TO MULTIPLE MYELOMA AND PRECURSORS THEREOF
[French]
PROCÉDÉS ASSOCIÉS À UN MYÉLOME MULTIPLE ET PRÉCURSEURS ASSOCIÉS
Applicants **
DANA-FARBER CANCER INSTITUTE, INC.
THE GENERAL HOSPITAL CORPORATION
Inventors
SKLAVENITIS PISTOFIDIS, Romanos
GETZ, Gad
GHOBRIAL, Irene
Priority Data
63/689,201
30.08.2024
US
63/698,902
25.09.2024
US
63/715,843
04.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3695 | |
| EPO | Filing, Examination, Granting | 26993 | |
| Japan | Filing, Examination, Granting | 3140 | |
| South Korea | Filing, Examination, Granting | 4136 | |
| USA | Filing, Examination, Granting | 14790 |
Total:
52,754
Contact Us
Abstract[English]
Disclosed herein are differences in the features of immune cell populations in subjects with monoclonal gammopathy of unknown significance (MGUS) or smoldering myeloma (SMM), compared to subjects with multiple myeloma (MM). These features are useful in methods for monitoring progression from MGUS or SMM to MM in a subject. In some instances, certain features are also useful in methods for predicting the response of a subject's MM to therapy.[French]
L'invention concerne des différences dans les caractéristiques de populations de cellules immunitaires chez des sujets atteints d'une gammopathie monoclonale de signification indéterminée (GMSI) ou de myélome multiple indolent (MMI), par comparaison avec des sujets atteints de myélome multiple (MM). Ces caractéristiques sont utiles dans des procédés de surveillance de la progression de GMSI ou de MMI à MM chez un sujet. Dans certains cas, certaines caractéristiques sont également utiles dans des procédés de prédiction de la réponse du MM d'un sujet à une thérapie.